Top

Published in:

01-08-2021 | Hepatocellular Carcinoma | Special Section: HCC Treatment

LI-RADS treatment response assessment of combination locoregional therapy for HCC

Authors: Marielia Gerena, Christopher Molvar, Mark Masciocchi, Sadhna Nandwana, Carl Sabottke, Bradley Spieler, Rishi Sharma, Leo Tsai, Ania Kielar

Published in: Abdominal Radiology | Issue 8/2021

Abstract

HCC incidence continues to increase worldwide and is most frequently discovered at an advanced stage when limited curative options are available. Combination locoregional therapies have emerged to improve patient survival and quality of life or downstage patients to curative options. The increasing options for locoregional therapy combinations require an understanding of the expected post-treatment imaging appearance in order to assess treatment response. This review aims to describe the synergy between TACE combined with thermal ablation and TACE combined with SBRT. We will also illustrate expected imaging findings that determine treatment efficacy based on the mechanism of tissue injury using the LI-RADS Treatment Response Algorithm.

Petrick JL, Florio AA, Znaor A, et al (2020) International trends in hepatocellular carcinoma incidence, 1978–2012. International Journal of Cancer 147:317–330. https://doi.org/10.1002/ijc.32723CrossRefPubMed

(2018) EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019

Heimbach JK, Kulik LM, Finn RS, et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67:358–380. https://doi.org/10.1002/hep.29086CrossRefPubMed

Aslam A, Do RKG, Kambadakone A, et al (2020) Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 12:738–753. https://doi.org/10.4254/wjh.v12.i10.738CrossRefPubMedPubMedCentral

Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52–60. https://doi.org/10.1055/s-0030-1247132CrossRefPubMed

Kudo M, Han G, Finn RS, et al (2014) Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial: HEPATOLOGY, Vol. XX, No. X, 2014 KUDO ET AL. Hepatology 60:1697–1707. https://doi.org/10.1002/hep.27290

Vincenzi B, Maio MD, Silletta M, et al (2015) Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis. PLOS ONE 10:e0133488. https://doi.org/10.1371/journal.pone.0133488CrossRefPubMedPubMedCentral

Lencioni R, Montal R, Torres F, et al (2017) Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology 66:1166–1172. https://doi.org/10.1016/j.jhep.2017.01.012CrossRefPubMed

Johnson PJ, Qin S, Park J-W, et al (2013) Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study. JCO 31:3517–3524. https://doi.org/10.1200/JCO.2012.48.4410CrossRef

10.

Kudo M, Ueshima K, Yokosuka O, et al (2018) Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial. The Lancet Gastroenterology & Hepatology 3:424–432. https://doi.org/10.1016/S2468-1253(18)30078-5CrossRef

11.

Llovet JM, Decaens T, Raoul J-L, et al (2013) Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. JCO 31:3509–3516. https://doi.org/10.1200/JCO.2012.47.3009CrossRef

12.

Llovet JM, Lencioni R (2020) mRECIST for HCC: Performance and novel refinements. Journal of Hepatology 72:288–306. https://doi.org/10.1016/j.jhep.2019.09.026CrossRefPubMed

13.

American College of Radiology Liver Imaging Reporting and Data System, v2018 CT/MR Manual

14.

Cools KS, Moon AM, Burke LMB, et al (2020) Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma. Liver Transplantation 26:203–214. https://doi.org/10.1002/lt.25673CrossRefPubMed

15.

Abdel Razek A a. K, El-Serougy LG, Saleh GA, et al (2020) Reproducibility of LI-RADS treatment response algorithm for hepatocellular carcinoma after locoregional therapy. Diagn Interv Imaging 101:547–553. https://doi.org/10.1016/j.diii.2020.03.008

16.

Chaudhry M, McGinty KA, Mervak B, et al (2020) The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology 294:320–326. https://doi.org/10.1148/radiol.2019191581CrossRefPubMed

17.

Kim SW, Joo I, Kim H-C, et al (2020) LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features. Eur Radiol 30:2861–2870. https://doi.org/10.1007/s00330-019-06623-9CrossRefPubMed

18.

Zhang Y, Wang J, Li H, et al (2020) Performance of LI-RADS version 2018 CT treatment response algorithm in tumor response evaluation and survival prediction of patients with single hepatocellular carcinoma after radiofrequency ablation. Ann Transl Med 8:388. https://doi.org/10.21037/atm.2020.03.120

19.

Seo N, Kim MS, Park M-S, et al (2020) Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with Liver Imaging Reporting and Data System version 2017. Eur Radiol 30:261–271. https://doi.org/10.1007/s00330-019-06376-5CrossRefPubMed

20.

Thibodeau-Antonacci A, Petitclerc L, Gilbert G, et al (2019) Dynamic contrast-enhanced MRI to assess hepatocellular carcinoma response to Transarterial chemoembolization using LI-RADS criteria: A pilot study. Magnetic Resonance Imaging 62:78–86. https://doi.org/10.1016/j.mri.2019.06.017CrossRefPubMed

21.

Shropshire EL, Chaudhry M, Miller CM, et al (2019) LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology 292:226–234. https://doi.org/10.1148/radiol.2019182135CrossRefPubMed

22.

Mendiratta-Lala M, Masch W, Shankar PR, et al (2019) Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys 103:169–179. https://doi.org/10.1016/j.ijrobp.2018.09.004CrossRefPubMed

23.

Gaba RC, Lewandowski RJ, Hickey R, et al (2016) Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria. Journal of Vascular and Interventional Radiology 27:457–473. https://doi.org/10.1016/j.jvir.2015.12.752CrossRefPubMed

24.

Inchingolo R, Posa A, Mariappan M, Spiliopoulos S (2019) Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. 25:16

25.

Ahmed M, Solbiati L, Brace CL, et al (2014) Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update. Radiology 273:241–260. https://doi.org/10.1148/radiol.14132958CrossRefPubMed

26.

Marrero JA, Kulik LM, Sirlin CB, et al (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750. https://doi.org/10.1002/hep.29913CrossRefPubMed

27.

Sutter O, Calvo J, N’Kontchou G, et al (2017) Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. Radiology 284:877–886. https://doi.org/10.1148/radiol.2017161413CrossRefPubMed

28.

Tameez Ud Din A, Tameez-ud-din A, Chaudhary FMD, et al Irreversible Electroporation For Liver Tumors: A Review Of Literature. Cureus 11:. https://doi.org/10.7759/cureus.4994

29.

Lu DSK, Raman SS, Vodopich DJ, et al (2002) Effect of Vessel Size on Creation of Hepatic Radiofrequency Lesions in Pigs: Assessment of the “Heat Sink” Effect. American Journal of Roentgenology 178:47–51. https://doi.org/10.2214/ajr.178.1.1780047CrossRefPubMed

30.

Goldberg SN, Gazelle GS (2001) Radiofrequency tissue ablation: physical principles and techniques for increasing coagulation necrosis. Hepatogastroenterology 48:359–367PubMed

31.

Young S, Golzarian J (2020) Locoregional Therapies in the Treatment of 3- to 5-cm Hepatocellular Carcinoma: Critical Review of the Literature. American Journal of Roentgenology 215:223–234. https://doi.org/10.2214/AJR.19.22098CrossRefPubMed

32.

Iezzi R, Pompili M, Posa A, et al (2016) Combined locoregional treatment of patients with hepatocellular carcinoma: State of the art. World J Gastroenterol 22:1935–1942. https://doi.org/10.3748/wjg.v22.i6.1935CrossRefPubMedPubMedCentral

33.

Rossi S, Garbagnati F, Lencioni R, et al (2000) Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 217:119–126. https://doi.org/10.1148/radiology.217.1.r00se02119CrossRefPubMed

34.

Chang Y, Jeong SW, Young Jang J, Jae Kim Y (2020) Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 21:. https://doi.org/10.3390/ijms21218165

35.

Hickey RM, Lewandowski RJ, Salem R (2016) Yttrium-90 Radioembolization for Hepatocellular Carcinoma. Seminars in Nuclear Medicine 46:105–108. https://doi.org/10.1053/j.semnuclmed.2015.10.011CrossRefPubMed

36.

Tang J, Liu F, Yuan H, et al (2020) Pretreatment Apparent Diffusion Coefficient as a Predictor of Response to Transcatheter Arterial Chemoembolization Immediately Combined with Radiofrequency Ablation for Treatment of Solitary Large Hepatocellular Carcinoma. Cancer Manag Res 12:10127–10138. https://doi.org/10.2147/CMAR.S270470CrossRefPubMedPubMedCentral

37.

Yuan H, Liu F, Li X, et al (2019) Transcatheter arterial chemoembolization combined with simultaneous DynaCT-guided radiofrequency ablation in the treatment of solitary large hepatocellular carcinoma. Radiol Med 124:1–7. https://doi.org/10.1007/s11547-018-0932-1CrossRefPubMed

38.

Yuan H, Liu F, Li X, et al (2019) Angio-CT-Guided Transarterial Chemoembolization Immediately in Combination with Radiofrequency Ablation for Large Hepatocellular Carcinoma. Academic Radiology 26:224–231. https://doi.org/10.1016/j.acra.2018.04.007CrossRefPubMed

39.

Wang Z-J, Wang M-Q, Duan F, et al (2013) Transcatheter arterial chemoembolization followed by immediate radiofrequency ablation for large solitary hepatocellular carcinomas. World J Gastroenterol 19:4192–4199. https://doi.org/10.3748/wjg.v19.i26.4192CrossRefPubMedPubMedCentral

40.

Yan J-Y, Zhang J-L, Wang M-Q, et al (2018) Combined transcatheter arterial chemoembolization and radiofrequency ablation in single-session for solitary hepatocellular carcinoma larger than 7 cm. Asia Pac J Clin Oncol 14:300–309. https://doi.org/10.1111/ajco.12817CrossRefPubMed

41.

Hoffmann R, Rempp H, Syha R, et al (2014) Transarterial chemoembolization using drug eluting beads and subsequent percutaneous MR-guided radiofrequency ablation in the therapy of intermediate sized hepatocellular carcinoma. European Journal of Radiology 83:1793–1798. https://doi.org/10.1016/j.ejrad.2014.06.031CrossRefPubMed

42.

Kim JH, Won HJ, Shin YM, et al (2011) Medium-Sized (3.1–5.0 cm) Hepatocellular Carcinoma: Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Radiofrequency Ablation Alone. Ann Surg Oncol 18:1624–1629. https://doi.org/10.1245/s10434-011-1673-8CrossRefPubMed

43.

Kim JW, Shin SS, Kim JK, et al (2013) Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization for the Treatment of Single Hepatocellular Carcinoma of 2 to 5 cm in Diameter: Comparison with Surgical Resection. Korean J Radiol 10

44.

Xu Z, Xie H, Zhou L, et al (2019) The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2019:. https://doi.org/10.1155/2019/8619096

45.

Voizard N, Cerny M, Assad A, et al (2019) Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging 10:121. https://doi.org/10.1186/s13244-019-0801-zCrossRefPubMedPubMedCentral

46.

Guan Y-S, Sun L, Zhou X-P, et al (2004) Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up. World Journal of Gastroenterology 10:3543–3548. https://doi.org/10.3748/wjg.v10.i24.3543CrossRefPubMedPubMedCentral

47.

Idée J-M, Guiu B (2013) Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: A review. Critical Reviews in Oncology/Hematology 88:530–549. https://doi.org/10.1016/j.critrevonc.2013.07.003CrossRefPubMed

48.

Chen C-S, Li F-K, Guo C-Y, et al (2016) Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 7:7241–7252. https://doi.org/10.18632/oncotarget.6892

49.

Kim SJ, Choi MS, Kang JY, et al (2009) Prediction of complete necrosis of hepatocellular carcinoma treated with transarterial chemoembolization prior to liver transplantation. Gut Liver 3:285–291. https://doi.org/10.5009/gnl.2009.3.4.285CrossRefPubMedPubMedCentral

50.

Miszczuk MA, Chapiro J, Geschwind J-FH, et al (2020) Lipiodol as an Imaging Biomarker of Tumor Response After Conventional Transarterial Chemoembolization: Prospective Clinical Validation in Patients with Primary and Secondary Liver Cancer. Transl Oncol 13:100742. https://doi.org/10.1016/j.tranon.2020.01.003CrossRefPubMedPubMedCentral

51.

Bae JS, Lee JM, Yoon JH, et al (2021) Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent–enhanced MRI. Radiology 203537. https://doi.org/10.1148/radiol.2021203537

52.

Zhao J, Zeng L, Wu Q, et al (2019) Stereotactic Body Radiotherapy Combined with Transcatheter Arterial Chemoembolization versus Stereotactic Body Radiotherapy Alone as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis and Systematic Review. Chemotherapy 64:248–258. https://doi.org/10.1159/000505739CrossRefPubMed

53.

Huo YR, Eslick GD (2015) Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol 1:756. https://doi.org/10.1001/jamaoncol.2015.2189CrossRefPubMed

54.

Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5:85–91. https://doi.org/10.1016/0360-3016(79)90044-0CrossRefPubMed

55.

Meng M-B, Cui Y-L, Lu Y, et al (2009) Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: A systematic review and meta-analysis. Radiotherapy and Oncology 92:184–194. https://doi.org/10.1016/j.radonc.2008.11.002CrossRefPubMed

56.

Seong J, Kim SH, Suh CO (2001) Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma1. Journal of Gastroenterology and Hepatology 16:883–889. https://doi.org/10.1046/j.1440-1746.2001.02533.xCrossRefPubMed

57.

Syljuåsen RG (2019) Cell Cycle Effects in Radiation Oncology. In: Wenz F (ed) Radiation Oncology. Springer International Publishing, Cham, pp 1–8

58.

Kimura T, Doi Y, Takahashi S, et al (2020) An overview of stereotactic body radiation therapy for hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 14:271–279. https://doi.org/10.1080/17474124.2020.1744434CrossRefPubMed

59.

Mastrocostas K, Jang H-J, Fischer S, et al (2019) Imaging post-stereotactic body radiation therapy responses for hepatocellular carcinoma: typical imaging patterns and pitfalls. Abdom Radiol 44(5):1795–1807. https://doi.org/10.1007/s00261-019-01901-yCrossRef

60.

Mendiratta-Lala M, Masch W, Owen D, et al (2020) Natural history of hepatocellular carcinoma after stereotactic body radiation therapy. Abdom Radiol 45:3698–3708. https://doi.org/10.1007/s00261-020-02532-4CrossRef

61.

Tezuka M, Hayashi K, Kubota K, et al (2007) Growth Rate of Locally Recurrent Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization: Comparing the Growth Rate of Locally Recurrent Tumor with That of Primary Hepatocellular Carcinoma. Dig Dis Sci 52:783–788. https://doi.org/10.1007/s10620-006-9537-yCrossRefPubMed

62.

Tétreau R, Llacer C, Riou O, Deshayes E (2017) Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother 22:170–175. https://doi.org/10.1016/j.rpor.2015.12.004CrossRefPubMed

Title: LI-RADS treatment response assessment of combination locoregional therapy for HCC
Authors: Marielia Gerena
Christopher Molvar
Mark Masciocchi
Sadhna Nandwana
Carl Sabottke
Bradley Spieler
Rishi Sharma
Leo Tsai
Ania Kielar
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Published in: Abdominal Radiology / Issue 8/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI: https://doi.org/10.1007/s00261-021-03165-x

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

LI-RADS treatment response assessment of combination locoregional therapy for HCC

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2021

Radiomics of hepatocellular carcinoma: promising roles in patient selection, prediction, and assessment of treatment response

LI-RADS treatment response algorithm for detecting incomplete necrosis in hepatocellular carcinoma after locoregional treatment: a systematic review and meta-analysis using individual patient data

Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis

Can procedure time for paracentesis be optimized based on bottle selection?

Acute cholecystitis in recent lung transplant patients: a single-institution series of 10 cases

Correction to: Artificial intelligence in assessment of hepatocellular carcinoma treatment response

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page